Noonan syndrome natural history, complications and prognosis: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 24: | Line 24: | ||
* [[Idiopathic pulmonary hypertension]] | * [[Idiopathic pulmonary hypertension]] | ||
==== | ====Oncologic Complications==== | ||
'''Patients with Noonan syndrome are at an increased risk for the development of hematologic and solid malignancies:''' | |||
* Juvenile myelomonocytic leukemia | |||
* Acute myelogenous leukemia | |||
* B-cell acute lymphoblastic leukemia | |||
* Embryonal rhabdomyosarcoma | |||
* Granular cell tumors | |||
* Pilocytic astrocytoma | |||
* Sertoli cell tumor | |||
* Malignant mastocytosis | |||
* Malignant epithelioid angiosarcoma | |||
====Developmental Complications==== | ====Developmental Complications==== | ||
====Psychological Complications==== | ====Psychological Complications==== | ||
Revision as of 03:41, 9 November 2013
|
Noonan syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Noonan syndrome natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Noonan syndrome natural history, complications and prognosis |
|
FDA on Noonan syndrome natural history, complications and prognosis |
|
CDC on Noonan syndrome natural history, complications and prognosis |
|
Noonan syndrome natural history, complications and prognosis in the news |
|
Blogs on Noonan syndrome natural history, complications and prognosis |
|
Risk calculators and risk factors for Noonan syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Serge Korjian, Yazan Daaboul
Overview
Natural History, Complications and Prognosis
What is known about the natural history of Noonan syndrome is based on limited long-term follow-up studies. The most important study on the clinical course of Noonan sydrome comes from Shaw et al. who studied 112 patients with clinical or genetic diagnosis of Noonan syndrome with a mean follow-up of 12 years.[1] Patients with documented feeding difficulties during infancy were found to have poorer outcomes. Those with feeding problems had a mean age of speaking in two-word phrases of 39 months, compared with 26 months in patients with no feeding difficulties. Furthermore, whereas only 12.5% of patients with no problems feeding required attendance at a school for children with special needs, 58% of patients with feeding problems required the same care. In general, special academic assistance was needed in 44% of patients, although academic achievement was comparable to the general population. The average adult height was 167.4 cm in males and 152.7 cm in females.[1]
During the study interval, 10 patients died, three of which were secondary to hypertrophic cardiomyopathy. In total, 19% of patients had hypertrophic cardiomyopathy. Other cardiac anomalies included pulmonary stenosis in 65% of patients half of which required intervention. No patients died secondary to arrhythmias. The overall mortality rate was approximately 9%, with age of death ranging from a 4 months to 61 years.[1] In general, adults with Noonan syndrome required close cardiac follow-up as on third of them had an ongoing cardiac problem requiring either medical treatment, defibrillation, or pacemaker placement. Markers of good prognosis included normal cardiac output at rest, peak right ventricular pressure of <100 mm Hg, normal pulmonary artery pressure, and absence of symptoms.[2][1]
Cardiac Complications
Below is a list of the most common cardiac complications of Noonan syndrome:[3]
- Right ventricular outflow tract obstruction
- Hypertrophic cardiomyopathy
- Dilated cardiomyopathy evolving from hypertrophic cardiomyopathy
- Restrictive cardiomyopathy
- Aortic insufficiency
- Aortic root dilation
- Aortic dissection
- Giant aneurysm of the sinuses of Valsalva
- Constrictive pericarditis
- Idiopathic pulmonary hypertension
Oncologic Complications
Patients with Noonan syndrome are at an increased risk for the development of hematologic and solid malignancies:
- Juvenile myelomonocytic leukemia
- Acute myelogenous leukemia
- B-cell acute lymphoblastic leukemia
- Embryonal rhabdomyosarcoma
- Granular cell tumors
- Pilocytic astrocytoma
- Sertoli cell tumor
- Malignant mastocytosis
- Malignant epithelioid angiosarcoma
Developmental Complications
Psychological Complications
References
- ↑ 1.0 1.1 1.2 1.3 Shaw AC, Kalidas K, Crosby AH, Jeffery S, Patton MA (2007). "The natural history of Noonan syndrome: a long-term follow-up study". Arch Dis Child. 92 (2): 128–32. doi:10.1136/adc.2006.104547. PMC 2083343. PMID 16990350.
- ↑ Smpokou P, Tworog-Dube E, Kucherlapati RS, Roberts AE (2012). "Medical complications, clinical findings, and educational outcomes in adults with Noonan syndrome". Am J Med Genet A. 158A (12): 3106–11. doi:10.1002/ajmg.a.35639. PMID 23165751.
- ↑ Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013). "Noonan syndrome". Lancet. 381 (9863): 333–42. doi:10.1016/S0140-6736(12)61023-X. PMID 23312968.
Template:Phakomatoses and other congenital malformations not elsewhere classified